Luveltamab tazevibulin

PreclinicalSmall molecule

Luveltamab tazevibulin is one of 50 small molecule programs targeting Relapsed/Refractory. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed/refractoryTerminated

Relapsed/refractoryPreclinical

Terminated

Competition

Competitive Landscape

62 competitors in Relapsed/refractory

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Phase 3

9 2

Rituxan

Roche

Phase 2

9 3

Venclexta

AbbVie

Phase 2

8 4

Fludara

Sanofi

Phase 2

7 5

Keytruda

Merck & Co.

Phase 2

4 6

Opdivo

Bristol-Myers Squibb

Phase 2

4 7

Adcetris

Pfizer

Phase 2

2 8

Gemzar

Johnson & Johnson

Phase 2

2 9

Velban

Eli Lilly

Phase 2

1 10

Eloxatin

Teva

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ovarian Cancer1 trial

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Terminated·SSutro Biopharma, Inc.·Phase 2/3·NCT05870748·600 enrolled

Non-Small Cell Lung Cancer1 trial

Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer

Withdrawn·SSutro Biopharma, Inc.·Phase 2·NCT06555263

Acute Myeloid Leukemia (AML)1 trial

A Phase 1/2, Open-label Study Evaluating the Efficacy, Safety, and Pharmacokinetics (PK) of Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With CBFA2T3::GLIS2 Acute Myeloid Leukemia (AML)

Terminated·SSutro Biopharma, Inc.·Preclinical·NCT06679582·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Luveltamab tazevibulin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Luveltamab tazevibulin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Luveltamab tazevibulin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sutro Biopharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSutro Biopharma, Inc.

Luveltamab tazevibulin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ovarian Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Acute Myeloid Leukemia (AML)1 trial

References

Drug Info

Quick Facts

Related News